← Leaderboards
Evan L Brittain
Vanderbilt University Medical Center
$13,630,303
Attributed
$22,107,481
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,507,481 · 10
FDA$1,600,000 · 1
By mechanism
R01$17,308,599 · 6
R33$2,271,883 · 1
R34$1,272,636 · 2
R61$773,113 · 1
R21$481,250 · 1
Top collaborators
- Anna R Hemnes8 shared
- Eric Douglas Austin6 shared
- Bruce M Damon5 shared
- Matthew S Freiberg5 shared
- Bradley Maron4 shared
- Thomas J Wang4 shared
- Sarah Sanders Jaser2 shared
- Douglas Ruderfer2 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Anna R Hemnes$10,524,693
- Alexander Tharrington Hawkins$2,097,749
- Margaret McCullough Benningfield$498,339
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsLinkPulmonary Arterial HypertensionParticipantSamplingMetabolicRight Ventricular FunctionPhenotypePathway InteractionsPlasmaClinical TrialsRandomizedPublishingPhysical ActivityCohortExerciseObesityPulmonary HypertensionImpairmentActivities Of Daily LivingInsulin ResistanceFunctional DisorderProteinsEvent
Grant awards (37)
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension$804,822
R01 · FY2025 · HL · contact PI
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study$763,088
R33 · FY2025 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$699,718
R01 · FY2025 · HL · contact PI
Effect of PDE5 Inhibition on Adipose Metabolism in Humans$643,414
R01 · FY2025 · DK · contact PI
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2025 · FD · contact PI
MhOVE-PPH Study: Mobile health interventiOn to improVe Exercise in Pediatric PH$260,614
R34 · FY2025 · HL
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study$740,089
R33 · FY2024 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$685,723
R01 · FY2024 · HL · contact PI
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension$678,896
R01 · FY2024 · HL · contact PI
Effect of PDE5 Inhibition on Adipose Metabolism in Humans$674,258
R01 · FY2024 · DK · contact PI
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2024 · FD · contact PI
MhOVE-PPH Study: Mobile health interventiOn to improVe Exercise in Pediatric PH$293,188
R34 · FY2024 · HL
Impact of Physical Activity, Sleep, and Genetic Background on Cardiovascular Risk in the All of Us Program$262,500
R21 · FY2024 · HL · contact PI
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension$816,993
R01 · FY2023 · HL · contact PI
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study$768,706
R33 · FY2023 · HL · contact PI
Effect of PDE5 Inhibition on Adipose Metabolism in Humans$696,114
R01 · FY2023 · DK · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$653,505
R01 · FY2023 · HL · contact PI
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2023 · FD · contact PI
Impact of Physical Activity, Sleep, and Genetic Background on Cardiovascular Risk in the All of Us Program$218,750
R21 · FY2023 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$798,826
R01 · FY2022 · HL · contact PI
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study$773,113
R61 · FY2022 · HL · contact PI
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure$759,572
R01 · FY2022 · HL · contact PI
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension$752,441
R01 · FY2022 · HL · contact PI
Effect of PDE5 Inhibition on Adipose Metabolism in Humans$696,044
R01 · FY2022 · DK · contact PI
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2022 · FD · contact PI
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure$787,763
R01 · FY2021 · HL · contact PI
Effect of PDE5 Inhibition on Adipose Metabolism in Humans$736,479
R01 · FY2021 · DK · contact PI
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure$790,627
R01 · FY2020 · HL · contact PI
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure$871,041
R01 · FY2019 · HL · contact PI
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction$728,870
R01 · FY2019 · HL
A Mobile Health Intervention in Pulmonary Arterial Hypertension$234,979
R34 · FY2019 · HL · contact PI
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure$233,692
R01 · FY2019 · HL · contact PI
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction$728,848
R01 · FY2018 · HL
A Mobile Health Intervention in Pulmonary Arterial Hypertension$234,851
R34 · FY2018 · HL · contact PI
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction$693,135
R01 · FY2017 · HL
A Mobile Health Intervention in Pulmonary Arterial Hypertension$249,004
R34 · FY2017 · HL · contact PI
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction$777,818
R01 · FY2016 · HL